Excalibur Management Corp Sells 8,742 Shares of Pfizer Inc. (NYSE:PFE)

Excalibur Management Corp decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 153,636 shares of the biopharmaceutical company’s stock after selling 8,742 shares during the period. Pfizer accounts for 1.6% of Excalibur Management Corp’s portfolio, making the stock its 11th largest position. Excalibur Management Corp’s holdings in Pfizer were worth $4,076,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in PFE. Nordea Investment Management AB boosted its holdings in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after acquiring an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI boosted its stake in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after purchasing an additional 159,984 shares in the last quarter. NFJ Investment Group LLC grew its position in Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock valued at $11,129,000 after purchasing an additional 43,719 shares during the last quarter. Copley Financial Group Inc. bought a new stake in Pfizer during the 3rd quarter valued at about $577,000. Finally, Zacks Investment Management raised its holdings in Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company’s stock worth $69,142,000 after buying an additional 235,243 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 2.2 %

PFE stock opened at $25.56 on Wednesday. The business’s 50-day moving average price is $26.14 and its 200-day moving average price is $27.00. The stock has a market cap of $144.96 billion, a P/E ratio of 18.13, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.